Search
US biotech Aldeyra Therapeutics (Nasdaq: ALDX) has received a third complete response letter from the American medicines regulator for its dry eye candidate reproxalap, sending shares down around 68%.
From thepharmaletter.comA new analysis warns that once-controlled childhood diseases could come roaring back if vaccine access declines – including diphtheria, a historic killer known as the “strangling angel.”Researchers...
From rawstory.comDanish pharma major Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting...
From thepharmaletter.comThe FDA approved an update to the neffy 1 mg prescribing information so that age is not a factor in when to use the epinephrine nasal spray for emergency treatment of type 1 allergic reactions,...
From healio.comComputer Software Validation (CSV) in pharma explained — regulations, the V-Model, risk-based strategies, EU GMP Annex 11, and how BGO Software helps you stay inspection-ready.
From bgosoftware.com








